The agreement is the first of its kind between the European Investment Bank and a corporate venture capital firm
The deal is worth $340 million and was completed in the US; Angelini Ventures had originally invested in 2024
Singapore-based biotech scale-up develops new therapy for cardiomyopathy based on mechanobiology
Danish start-up works on an RNA molecule to treat neurological disorders such as epilepsy and Parkinson's disease
Click here to read previous Newsletters
Subscribe to the newsletter
yes
en
* I agree that my personal data will be used in accordance with the Privacy and Cookie Policy.
* I authorize the processing of my personal data to be updated on new arrivals and for direct marketing purposes related to the services offered.